Date:December 10, 2024
Bio Usawa has a singular focus: to build the manufacturing capacity required to make and supply high quality, effective and affordable antibody-based biosimilars for ophthalmic, cancer, autoimmune and infectious diseases. We are applying our 100+ years of combined experience in the industry in close partnership with governments, agencies, educators and health professionals to tap into a talented domestic workforce for making powerful biomedicines in Africa, by Africans, for Africans and beyond.
Click here to learn more about our Company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.
Bio Usawa Biotechnology Ltd. (Bio Usawa) and Bioeq AG today announced a groundbreaking agreement that will bring a life-changing biosimilar medicine—ran…
July 2025Dr. Menghis Bairu, CEO, Co-Founder and President of Bio Usawa (BUI), together with Dr. Miriam Mutebi, internationally recognized surgical oncologist and…
June 2025Eric Karikari – Boateng, MSc, Head of Global Regulatory Strategy at Bio Usawa (BUI), and Elise Brownell, PhD, Chief of Staff, lead the Company’s Executi…
June 2025